Charles River Laboratories International (CRL)
(Delayed Data from NYSE)
$204.46 USD
+1.69 (0.83%)
Updated Dec 8, 2023 04:00 PM ET
After-Market: $204.47 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum D VGM
Charles River Laboratories (CRL) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$218.69 | $260.00 | $189.00 | 7.85% |
Price Target
Based on short-term price targets offered by 13 analysts, the average price target for Charles River Laboratories comes to $218.69. The forecasts range from a low of $189.00 to a high of $260.00. The average price target represents an increase of 7.85% from the last closing price of $202.77.
Analyst Price Targets (13)
Broker Rating
Charles River Laboratories currently has an average brokerage recommendation (ABR) of 1.62 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 13 brokerage firms. The current ABR compares to an ABR of 1.62 a month ago based on 13 recommendations.
Of the 13 recommendations deriving the current ABR, nine are Strong Buy, representing 69.23% of all recommendations. A month ago, Strong Buy represented 69.23%.
Broker Rating Breakdown

Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 8 | 8 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 4 | 4 | 4 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.62 | 1.62 | 1.62 | 1.67 | 1.67 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/22/2023 | William Blair | Maxwell A Smock | Strong Buy | Strong Buy |
9/22/2023 | Guggenheim Securities | Jack D Wallace | Strong Buy | Strong Buy |
9/22/2023 | Robert W. Baird & Co. | Eric W Coldwell | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.62 |
ABR (Last week) | 1.62 |
# of Recs in ABR | 13 |
Average Target Price | $217.15 |
LT Growth Rate | 8.90% |
Industry | Medical Services |
Industry Rank by ABR | 88 of 252 |
Current Quarter EPS Est: | 2.40 |